Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

Bullboard Posts

Comment by Findingmoneyon Jun 16, 2020 8:44am

88 Views

Post# 31154789

RE:Stop your childish reactions.

Hippophilia is just having fun, take it for what it is worth. As for this company nothing has changed and we are still awaiting results. If it retraces, you have an opportunity to increase your position, but unlike horses try not to get skittish from noises unknown, or do so and sell away and free your mind from the Stress-Reward/Loss ratio, as for myself I have been here awhile and I have the popcorn so I am going to enjoy the show.

Bullboard Posts

How one company is disrupting PoC testing